EN DE
Watch KP Tissue Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

KP Tissue Inc (KPT) fair value: what the stock is really worth

As of Nov 12, 2026: fair value (intrinsic value) of KP Tissue Inc stock C$13.47, price C$12.40, upside +8.6%, quality 73 out of 100. Rating: fairly valued. Calculated from audited financials with 9 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive CA · ISIN CA48265Y1043

KT KP Tissue Inc logo Thin data Nov 12, 2026

KP Tissue Inc

KPT · TO

Solid company and rising price, but the stock is already about fairly priced: meets 2 of 3 rules.

Get notified free when this changes
Quality 73/100 
Rising price (uptrend) 
Generates free cash flow 
Ranks above peers (8/10) 
Fair value C$13.47 · Fairly valued 
5.8% dividend yield · Watch coverage
Moderate moat 60/100 · thin data
Weak Growth (revenue 3y −66.2 %/yr in CAD) 
Thin data 
Watch KP Tissue Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$13.18 C$6.62 Fair Value C$13.47 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range C$6.62 – C$13.18 · fair‑value band C$9.43 – C$17.51 · the C$12.40 price screens below the C$13.47 fair value. As of Nov 12, 2026.

Follow KP Tissue in your weekly email

Every Wednesday you see whether KP Tissue is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

KP Tissue Inc., through its interest in Kruger Products Inc., produces, distributes, markets, and sells a range of disposable tissue products in Canada and the United States. The company operates through the Consumer and Away-From-Home segments.

Show moreShow less

It offers bathroom and facial tissues, paper towels, and napkins. The company markets its products under Cashmere, Purex, Scotties, SpongeTowels, Bonterra and White Cloud. brand names, as well as under private labels.

It sells its products through the retail channels, such as grocery stores, mass merchandisers, club stores, drug stores, and convenience stores; and distributors to businesses involved in property management, health care, food service, manufacturing and lodging, education, and lodging.

KP Tissue Inc. was incorporated in 2012 and is headquartered in Mississauga, Canada.

Stock analysis

KP Tissue Inc (KPT) currently trades at C$12.40, while our model-based Fair Value estimate is C$13.47, so the stock looks roughly fairly valued today (gap 7.9%).

Show more

Valuation

Bull case: the Multiples group reads highest at a median of C$17.80 per share, and 3 of the 9 models we run sit above the C$12.40 price.

Bear case: the Asset-Based group reads lowest at C$4.66, and 6 of the 9 models stay below the price. Data coverage for this calculation is low.

Scenario range: C$9.43 (bear) to C$17.51 (bull), the price of C$12.40 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 73/100 (solid quality), in the Consumer Defensive sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

KP Tissue Inc reported revenue of C$0 in FY2025 versus C$0 in FY2021. Reported net income was C$8.5M in FY2025, compounding +61.9%/yr from FY2021.

Key figures

Market cap C$124M (≈ $87.2M) Micro · P/E ratio 14.3 · EPS (TTM) C$0.8700 · Dividend yield 5.8% · Return on equity 12.5% · Return on assets (EBIT) −3.7% (5-year average) · EPS growth (YoY) −5.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 41% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −31% fair-value upside, at 9%, KPT screens cheaper than that median.

Fair Value models

Bear C$9.43 Fair Value C$13.47 Bull C$17.51
Price C$12.40 · Upside +8.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (C$0.1303 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income C$6.17 C$6.88 C$8.13 65
P/E Multiple C$13.35 C$17.80 C$22.25 63
EV/EBITDA C$309.27 C$412.36 C$515.45 61
All 9 models by family
Earnings-Based
Graham-Dodd C$5.76 C$7.04 C$7.93 58
Dividend Discount
Gordon GGM C$5.39 C$5.81 C$6.44 60
DDM Multi-Stage C$5.39 C$6.42 C$7.74 58
Multiples
P/E Multiple C$13.35 C$17.80 C$22.25 63
P/B Multiple C$6.73 C$8.98 C$11.22 55
EV/EBITDA C$309.27 C$412.36 C$515.45 61
Asset-Based
NCAV (Graham) C$3.48 C$4.66 C$6.96 51
Economic Profit
Residual Income C$6.17 C$6.88 C$8.13 65
Growth Earnings
Growth-Adj P/E C$9.43 C$13.47 C$17.51 58

Open the full fair value analysis →

Quality Score breakdown

Overall quality 73/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 97
How calm the share price moves, does not count
Price momentum 57
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 81
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 7/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+52.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+46.5%
Dividend (yield on the price)5.8%

Watch KPT, get fair value alerts →

Compare KP Tissue Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 241 stocks

Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 73 · Top 25%
Fair Value upside +8.6% · Above median
Profitability
Return on equity (12 months) 12.5% · Above median
Return on assets 11.9% · Top 25%
Operating margin (12 months) 0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median
Dividend yield (12 months) 5.8% · Top 25%

Valuation Multiplesvs Household & Personal Products median · lower = cheaper

P/E (12 months) 14.3× · Cheaper than median
P/B 1.25× · Cheaper than median
PEG 1.44× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)45 · sector 35
FUTURE (revenue growth)0 · sector 19
PAST (return on equity)50 · sector 28
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)100 · sector 52

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Godrej Consumer Products Limited GODREJCP ₹876.50 ₹1,146 +31% vs KPT
Puig Brands, S.A PUIG €20.36 €24.28 +19% vs KPT
Henkel AG HEN €78.00 €83.75 +7% vs KPT
Beiersdorf Aktiengesellschaft, BEI €84.08 €69.09 −18% vs KPT
The Clorox Company CLX $108.20 $74.29 −31% vs KPT
Church & Dwight Co CHD $111.73 $65.04 −42% vs KPT
Colgate-Palmolive Company CL $97.90 $56.16 −43% vs KPT
Marico Limited MARICO ₹902.00 ₹493.84 −45% vs KPT
The Estée Lauder Companies Inc EL $110.51 $44.21 −60% vs KPT
Hindustan Unilever Limited HINDUNILVR ₹1,974 ₹775.25 −61% vs KPT

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

KP Tissue Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "KP Tissue Inc Fair Value". https://www.fairvalue-calculator.com/stock/KPT

Frequently asked questions

Is KP Tissue Inc (KPT) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of C$13.47 versus a price of C$12.40, about +9% upside (fairly valued).
What is the fair value of KPT?
Our model-based fair value for KP Tissue Inc is C$13.47 (as of Nov 12, 2026), built from audited fundamentals. The current price: C$12.40.
What is the quality score of KPT?
KP Tissue Inc has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for KP Tissue Inc (KPT)?
Our model-based price target is the fair value of C$13.47 (as of Nov 12, 2026) from 9 valuation models. Cautious scenario C$9.43, optimistic scenario C$17.51. It is a calculation from audited fundamentals, not an analyst target.
What is the KP Tissue Inc stock forecast for 2026?
Our models put fair value at C$13.47, about +9% upside versus a price of C$12.40 (fairly valued). Cautious scenario C$9.43, optimistic scenario C$17.51. The calculation is refreshed regularly with new filings.
Does KP Tissue Inc pay a dividend?
KP Tissue Inc currently shows a dividend yield of 5.81% relative to its recent price (as of Nov 12, 2026).
How much is the dividend of KP Tissue Inc (KPT) and when is the ex-dividend date?
KP Tissue Inc pays a dividend of C$0.72 per share a year, a dividend yield of 5.8%. The last ex-dividend date was Sep 29, 2026. A dividend has been paid every year since at least 2013. The payout ratio is 82.8% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of KP Tissue Inc (KPT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For KP Tissue Inc it is C$13.47 per share (as of Nov 12, 2026), against a price of C$12.40. It is the blended result of 9 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is KP Tissue Inc stock overvalued or undervalued in 2026?
As of Nov 12, 2026, KPT trades below its calculated fair value: price C$12.40, fair value C$13.47, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KPT?
No. The price is what the market pays today (C$12.40); the fair value is what the company's own numbers justify (C$13.47). For KP Tissue Inc the two are C$1.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is KP Tissue Inc worth?
The market values KP Tissue Inc at about C$124M (market capitalisation, as of Nov 12, 2026). Per share that is C$12.40; our models calculate a fair value of C$13.47 per share.
What do the bullish and bearish scenarios say about KPT?
Our models span a range for KP Tissue Inc: cautious scenario C$9.43, base C$13.47, optimistic C$17.51 per share (as of Nov 12, 2026, price C$12.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KPT?
KP Tissue Inc trades at a price-to-earnings ratio of 14.3 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of C$13.47 is built from several models across several years. Other multiples: PEG 1.4, P/B 1.3.
What is the PEG ratio of KPT?
The PEG ratio of KP Tissue Inc is 1.44 (P/E divided by earnings growth, as of Nov 12, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of KP Tissue Inc (KPT)?
Balance-sheet figures for KP Tissue Inc (as of Nov 12, 2026): return on equity 12.5%. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is KPT from its 52-week high?
KP Tissue Inc trades at C$12.40, about 6% below its 52-week high of C$13.18 and 41% above the low of C$8.82 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of C$13.47 is for.
Which stocks are comparable to KP Tissue Inc?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is KP Tissue Inc stock attractive at the current price?
The data as of Nov 12, 2026: price C$12.40, calculated fair value C$13.47 (+9%), Quality Score 73/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KPT calculated?
We run KP Tissue Inc through 9 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of C$13.47 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. KP Tissue Inc currently trades 8% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of KP Tissue Inc (KPT)?
The closing price on Nov 12, 2026 was C$12.40. Our model-based fair value is C$13.47, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with KP Tissue Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (C$9.43 to C$17.51) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of KP Tissue Inc

How large is the market capitalisation of KP Tissue Inc (KPT)?
The market capitalisation of KP Tissue Inc is C$124M (≈ $87.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of KP Tissue Inc (KPT)?
Earnings per share at KP Tissue Inc are C$0.8700 (price ÷ EPS = P/E 14.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of KP Tissue Inc (KPT)?
The dividend yield of KP Tissue Inc is 5.8% (payout 82.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of KP Tissue Inc (KPT)?
The return on equity (ROE) of KP Tissue Inc is 12.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of KP Tissue Inc (KPT)?
On an EBIT basis the return on assets of KP Tissue Inc is −3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast are earnings growing at KP Tissue Inc (KPT)?
Earnings per share at KP Tissue Inc are growing −5.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch KP Tissue Inc in the live analysis

One click puts KP Tissue Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.